title: Monocyte derivatives promote angiogenesis and myocyte survival in a model of myocardial infarction.
abstract: In this study, we have investigated the hypothesis that previously reported beneficial effect of peripheral blood mononuclear cells cultured under angiogenic conditions on cardiovascular function following ischemia is not limited to EPCs but also to monocytes contained therein. We first purified and analyzed the phenotype and secretome of human and murine blood monocytes cultured under angiogenic conditions (named MDs for monocyte derivatives) and tested their effect in a mouse model of myocardial infarction (MI). FACS analysis of MDs shows that these cells express mature endothelial cell markers and that their proliferative capacity is virtually absent, consistent with their end-differentiated monocytic ontogeny. MDs secreted significant levels of HGF, IGF-1, MCP-1, and sTNFR-1 relative to their monocyte precursors. MDs were unable to form vascular networks in vitro when cultured on matrix coated flasks. Treatment of murine HL-1 cardiomyocyte cell line with MD-conditioned medium reduced their death induced by TNF-alpha, staurosporine, and oxidative stress, and this effect was dependent upon MD-derived sTNFR-1, HGF, and IGF-1. We further demonstrate that MD secretome promoted endothelial cell proliferation and capacity to form vessels in vitro and this was dependent upon MD-derived MCP-1, HGF, and IGF-1. Echocardiography analysis showed that MD myocardial implantation improved left ventricle fractional shortening of mouse hearts following MI and was associated with reduced myocardial fibrosis and enhancement of angiogenesis. Transplanted MDs and their secretome participate in preserving functional myocardium after ischemic insult and attenuate pathological remodeling.
authors.affiliation: Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Bouchentouf
authors.forename: P
authors.initials: P
authors.lastname: Paradis
authors.forename: K A
authors.initials: KA
authors.lastname: Forner
authors.forename: J
authors.initials: J
authors.lastname: Cuerquis
authors.forename: M N
authors.initials: MN
authors.lastname: Boivin
authors.forename: J
authors.initials: J
authors.lastname: Zheng
authors.forename: M R
authors.initials: MR
authors.lastname: Boulassel
authors.forename: J P
authors.initials: JP
authors.lastname: Routy
authors.forename: E L
authors.initials: EL
authors.lastname: Schiffrin
authors.forename: J
authors.initials: J
authors.lastname: Galipeau
mesh_terms: D000818:Animals; D017209:Apoptosis; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000378:metabolism; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000166:cytology / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D017228:Hepatocyte Growth Factor / Q000378:metabolism; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009000:Monocytes / Q000378:metabolism* / Q000637:transplantation; D032342:Muscle Cells / Q000166:cytology*; D009203:Myocardial Infarction / Q000628:therapy*; D018919:Neovascularization, Physiologic; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000378:metabolism; D019311:Staurosporine / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D020257:Ventricular Remodeling
chemical_list: D018932:Chemokine CCL2; D047888:Receptors, Tumor Necrosis Factor, Type I; D014409:Tumor Necrosis Factor-alpha; D017228:Hepatocyte Growth Factor; D007334:Insulin-Like Growth Factor I; D019311:Staurosporine